Alkem Laboratories Limited on May 28, 2026, announced that its Board of Directors has recommended a final dividend of ₹10 per equity share of face value ₹2 each for the financial year ended March 2026. The announcement was made to the NSE following the conclusion of the board meeting held on the same day.

Total FY26 Payout Rises to ₹53 Per Share

The final dividend of ₹10 per share comes on top of the interim dividend of ₹43 per share declared by the board on February 13, 2026. This takes the aggregate dividend payout for FY26 to ₹53 per equity share, representing a meaningful increase from the total FY25 payout of ₹45 per share, which comprised an interim dividend of ₹37 and a final dividend of ₹8. The year-on-year increase in total payout stands at approximately 17.8%.

Dividend History Reveals a Structured Payout Pattern

Alkem's dividend history over the past several years reflects a consistent two-tranche payout approach, with an interim dividend declared in February and a final dividend recommended in May each year. The historical total annual payouts are as follows:

Excluding the FY23 special dividend component, the underlying payout trend shows a steady upward trajectory from FY24 through FY26, indicating improving cash generation and a management commitment to rewarding shareholders on a recurring basis. The FY26 total of ₹53 per share is the highest aggregate payout in the data series excluding the FY23 special dividend year.

Dividend Yield and Market Context

Since the quote data was not available at the time of this report, the dividend yield calculation will be updated upon availability of the current market price. For reference, Alkem's 52-week price range on the NSE will determine whether the stock is trading closer to its annual high or low, which in turn provides context for the effective yield that investors entering at current levels would receive on the announced ₹10 final dividend and the full-year ₹53 payout. Investors should note that the final dividend is subject to approval by shareholders at the upcoming Annual General Meeting before it is formally declared and paid.

Company Background

Alkem Laboratories is one of India's leading pharmaceutical companies, with a significant presence in the branded generics segment domestically and a growing international generics business. The company's equity shares are listed on both the NSE and BSE under the symbol ALKEM with ISIN INE540L01014. Its consistent dividend payouts are supported by strong domestic formulations revenue and improving profitability in the US generics market.

What This Means for Investors

The ₹10 final dividend, while modest on a standalone basis relative to the interim payout, is significant as a signal of management's confidence in the company's financial position at year-end. The progressive increase in total annual payouts from ₹40 in FY24 to ₹45 in FY25 and now ₹53 in FY26 points to a disciplined capital return policy. Investors tracking Alkem should note the record date, once announced, to ensure eligibility for the final dividend, and monitor the AGM outcome for formal shareholder approval.